Technology

A live-cell uptake platform that runs on equipment you already trust

The DrugUptech screening platform follows compound accumulation in living cells in real time, without lysis, washing, radiolabelling or chemical modification of the compound.

Detection principle

Accumulation read as depletion from the medium, using a proprietary fluorescent reporter

The platform operates in two detection modes and picks the right one for each compound during set-up:

  • Displacement mode. The reporter responds to the compound directly. Works for a broad range of chemotypes with no intrinsic fluorescence.
  • Direct mode. For compounds that fluoresce in the detection window, such as fluoroquinolones and tetracyclines, their own emission is followed.

Both modes give a complete kinetic profile from a single well, rather than a series of independently prepared endpoints.

What you get

Readouts that change decisions

% accumulation

Fraction of applied compound associated with cells, normalised to benchmarks run on the same plate.

Kinetics

Uptake rate, half-time and plateau from a one-phase association fit to the live trace.

Efflux contribution

Energy supplementation separates active efflux from reduced permeability.

Viability & efficacy

Optional MIC, growth or cytotoxicity readouts alongside uptake, so potency and accumulation are compared directly.

Specifications

Assay at a glance

Format
Black 96-well plates, standard fluorescence plate reader
Compound requirements
Unmodified, no label; typically µM working concentrations
Limit of detection
Around 150 nM for reporter-responsive compounds
Time to first data
Minutes for bacteria; hours for mammalian cells and tissue
Solvent tolerance
Up to 0.5% v/v DMSO; ethanol preferred where soluble
Compound scope
Screened against a library of 55 clinically approved drugs across diverse chemotypes
Readouts
% accumulation, kinetics, efflux contribution, viability or efficacy
Technology readiness
TRL 6: validated in relevant laboratory environments, pilot studies ongoing
Validated systems

Organisms and cell systems already on the platform

We can also set up your own strains, cell lines or tissue as part of a project.

Gram-negative bacteria

  • Pseudomonas aeruginosa PA01
  • Acinetobacter baumannii AYE
  • Klebsiella pneumoniae
  • Escherichia coli

Gram-positive & fungi

  • MRSA
  • Staphylococcus epidermidis
  • Mycobacterium smegmatis
  • Candida albicans
  • Candida tropicalis

Mammalian cells

  • Caco-2 (intestinal epithelium)
  • HEK293T
  • Further lines set up on request

Plant systems

Benchmarks available ColistinCeftazidimeRifampicinGentamicinTetracyclineCiprofloxacin
Rifampicin accumulation at 25 micromolar in AYE, PA01 and Klebsiella over 30 minutes
Rifampicin, 25 µM, in three Gram-negative pathogens. Mean ± SD, n = 3.
Efflux vs permeability

Two mechanisms, one symptom. We tell them apart.

Reduced permeability and active efflux both leave less compound inside the cell, so an accumulation deficit alone does not say which is the problem. Because our readout is kinetic and cheap to repeat, we can change the cell's energy state and watch the response. Adding glucose fuels proton-antiporter pumps: if accumulation drops, efflux is the culprit.

See the full dataset
Comparison

How it compares with existing accumulation methods

CapabilityDrugUptechLC-MS/MS lysate assaysRadiolabelled uptakePAMPA / Caco-2 permeability
Real-time kinetic dataYesNo, endpointsNo, endpointsLimited
Unmodified compoundYesYesNeeds labelYes
Live, intact cellsYesLysedWashed pelletsArtificial or monolayer
Bacteria and fungiYesYesYesNo
Plant cells and tissueYesRareRareNo
Standard plate reader onlyYesMass spectrometerScintillation countingYes
Throughput and scalabilityHighMediumLowHigh

Want to run your compounds on the platform?

Send us a shortlist and the organism or cell system you care about. We will confirm detection mode and propose a scope within a week.